Mimedx Group Inc
Research Mimedx Group Inc (MDXG) on Bullrun: valuation model: 67.9% overvalued, market cap USD 703.85M, P/E 122.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMDXG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal67.9% overvalued
- Market capUSD 703.85M
- P/E122.3
- Financial periodQ2 2026
- RevenueUSD 64.36M
- Net income-USD 14.84M
- Free cash flow-USD 10.72M
- Gross margin69.0%
Valuation Snapshot
Bullrun's latest valuation model marks Mimedx Group Inc as 67.9% overvalued; latest market cap is USD 703.85M; P/E is 122.3.
Peer valuation comparison
Latest P/E is 122.28x versus a Healthcare sector median of 24.6x (397.1% above).
Latest P/E is 122.28x versus a United States median of 23.85x (412.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 418.63M | USD 48.58M | USD 72.97M | 82.6% | 0.32 | USD 166.12M | USD 17.97M | USD 256.55M |
| FY2024 | USD 348.88M | USD 42.42M | USD 64.52M | 82.8% | 0.28 | USD 104.42M | USD 18.83M | USD 193.11M |
| FY2023 | USD 321.48M | USD 58.23M | USD 24.79M | 83.0% | 0.37 | USD 82.00M | USD 49.10M | USD 142.72M |
| FY2022 | USD 267.84M | -USD 30.20M | -USD 19.41M | 82.0% | -0.33 | USD 65.95M | USD 48.59M | -USD 17.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 703.85M | 122.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.00B | 21.2 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.41B | 34.4 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.28B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 316.00M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 676.03M | n/a | n/a | n/a |
About Mimedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Mimedx Group Inc overvalued or undervalued?
Bullrun's valuation model currently marks Mimedx Group Inc as 67.9% overvalued.
What is Mimedx Group Inc's market cap?
Mimedx Group Inc's market capitalization is USD 703.85M.
What is Mimedx Group Inc's P/E ratio?
Mimedx Group Inc's price-to-earnings (P/E) ratio is 122.3.
What does Mimedx Group Inc do?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.